TriCert Investment Counsel Inc.’s iShares Biotechnology ETF IBB Stock Holding History

TriCert Investment Counsel Inc.’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$231K	Buy	+1,215	New	+$209K	0.02%	86

Other funds holding IBB

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

AFG

Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

TriCert Investment Counsel Inc.'s IBB Position: Q2 2026 in Review

TriCert Investment Counsel Inc. opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 1,215 shares worth $231K. The stake represents 0.02% of the portfolio and ranks #86 among its holdings.

650 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

TriCert Investment Counsel Inc. held 1,215 shares of iShares Biotechnology ETF worth $231K as of Q2 2026.
iShares Biotechnology ETF was a new TriCert Investment Counsel Inc. position in Q2 2026.
iShares Biotechnology ETF made up 0.02% of TriCert Investment Counsel Inc.'s portfolio in Q2 2026, its #86 holding.
650 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on TriCert Investment Counsel Inc.'s 13F filing for Q2 2026, filed 10 Aug 2026.